Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 9INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Gynecologic 1

Conditions

Recurrence 1Multiple Myeloma 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 604Carboplatin 372Paclitaxel 282Cisplatin 267Gemcitabine 252Pemetrexed 193Bevacizumab 190Docetaxel 185Nivolumab 181Injections 167Cyclophosphamide 147atezolizumab 138Fluorouracil 133Capecitabine 133Oxaliplatin 132Dexamethasone 127Fulvestrant 113durvalumab 112130-nm albumin-bound paclitaxel 110fludarabine 101Cetuximab 100Leucovorin 97Rituximab 94venetoclax 90Lenalidomide 83enzalutamide 77Prednisone 76Azacitidine 74Irinotecan 72Ipilimumab 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Clarithromycin × 1 year × Clear all
NCT07341100 2026-06-01

Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2 Active not recruiting
20 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

NCT02343042 2026-05-04

STOMP

Karyopharm Therapeutics Inc

Phase 1/2 Active not recruiting
300 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡